3 Reasons for GlaxoSmithKline to Cheer

GlaxoSmithKline’s (NYSE: GSK) drug pipeline is showing strength, while Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) look well-placed, too.

Feb 2, 2014 at 2:30PM

Investors in GlaxoSmithKline (NYSE:GSK) have had reason to cheer recently, as the U.K.-based pharmaceutical giant has had three positive pieces of news flow surrounding its drug pipeline:

1. The company announced that a phase 3 study of the combination of Tafinlar and Mekinist in metastatic melanoma met its primary endpoint of progression-free survival. The study compared those results with the single agent therapy of Tafinlar, and furthermore, the company expects to receive additional positive results when the combination of the two drugs is compared to Vemurafenib later in the year.

2. GlaxoSmithKline received positive opinion from the CHMP, or Committee for Medicinal Products for Human Use, in Europe for once-weekly Eperzan for the treatment of type 2 diabetes. As with the FDA approval process, a positive opinion is one of the final steps before the European Commission grants marketing authorization, with the final decision being expected before the end of March.

3. ViiV -- a joint venture among GlaxoSmithKline, Pfizer (NYSE:PFE), and Shionogi -- announced the approval of an HIV medicine called Tivicay in Europe. It will be used in combination with other anti-retroviral medicinal products for the treatment of HIV-infected adults and adolescents older than 12.

These three pieces of encouraging news flow highlight the depth of the company's drug pipeline, as well as its diversity. Indeed, GlaxoSmithKline appears to be well placed to benefit from further upbeat news flow in the future, with the company continuing to invest heavily in its research-and-development program. The capital raised from the sale of brands such as Ribena and Lucozade looks set to be poured back into the drug pipeline, so future years could hold further progress for the company as it seeks to spend more to make more.

Despite the upbeat news flow, shares haven't made the most encouraging of starts to the year, being down 3.5% and in line with a weaker S&P 500 index over the past month. However, GlaxoSmithKline appears to offer decent value at current levels, with its yield providing evidence that shares may not be so highly priced. Indeed, shares currently yield 5%, which is considerably higher than the S&P yield of around 2%.

It also compares favorably with other health-care majors such as Pfizer and AbbVie (NYSE:ABBV). They both yield 3.2%, and although both figures are more than 50% higher than that of the S&P 500, GlaxoSmithKline offers a considerably higher income, which could prove to be highly beneficial during a period of low interest rates.

Of course, Pfizer and AbbVie continue to offer more than just a higher yield than the S&P 500. Both companies (like GlaxoSmithKline) possess strong drug pipelines, and although recent quarterly updates contained disappointing headline figures, there were clear reasons for this. Restructuring costs affected Pfizer, while generic competition hurt AbbVie's results, although both companies seem to have sound strategies with which to overcome their present challenges.

So with 2014 having gotten off to a positive start for GlaxoSmithKline, it could be a stock to watch. Management seem to be doing the right things in terms of selling off consumer brands to further strengthen the drug pipeline, which could lead to further positive news flow in future. In the meantime, investors looking for an income may find a 5% yield too good to miss out on.

The Motley Fool's top stock for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers